Abstract: Methods of improving a condition in a subject are provided herein. Aspects of the methods include at least partially restoring normal function of a central nervous system endocrine gland in a manner sufficient to improve the condition in the subject. In some instances, the condition is an aging associated condition. Aspects of the invention further include compositions, systems and devices for practicing the methods.

Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.

Abstract: The present technology provides a cell based assay for identifying compounds that modulate store-operated ionic calcium levels using itpr mutant cell lines, such as itpr-ku cells, which have abnormal ionic calcium levels.

Abstract: The present invention is based in part on the regulation of macrophages. Additionally, the present invention provides methods for the treatment of various diseases and disorders using a compound which regulates macrophage function.

Abstract: This document discloses molecules having the following formula (“Formula I”):

Abstract: The invention relates to a sterile wound dressing having a backing and a nonabsorbent elastomer wound contact layer, wherein the elastomer matrix is formed by a synthetic three-block elastomer, preferably a copolymer of polystyrene block and polyolefin block (SEPS, SEBS, SEEPS, etc.) or mixtures thereof, wherein the total polymer content is less than 3.2 wt %, in particular 3.0 wt % or less, preferably 2.6 wt % or less, and is plasticized by an apolar oil and/or petroleum jelly.

Abstract: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.

Abstract: A method of treating cancer by inhibiting expression of ubiquitin associated and SH3 domain containing B (UBASH3B) gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof.

Abstract: ?-Aminoamidine polymers and methods of preparing a-aminoamidine polymers by reacting by reacting one or more amines with one or more isocyanides and one or more aldehydes are described. Methods of preparing a-aminoamidine polymers from commercially available starting materials are also provided, wherein the starting materials are racemic or stereochemically pure. a-Aminoamidine polymers or salt forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems and for other purposes as well such as, for example, coatings, additives, excipients, plastics, and materials, etc. Given the amino moiety of these ?-aminoamidine polymers, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive ?-aminoamidine polymers and polynucleotides can be prepared. The inventive ?-aminoamidine polymers may also be used in preparing microparticles for drug delivery.

Abstract: The present invention provides biomarkers for sensitive, specific, accurate and quantitative diagnosis and assessment of chronic hypoxia. In particular, the present invention provides 2-hydroxyglutarate as a biomarker that is differentially produced in chronic hypoxia. Furthermore, embodiments of the invention are able to differentiate between chronic and acute hypoxia. Assays for levels of 2-hydroxyglutarate may be used alone or in conjunction with additional biomarkers of hypoxia to increase the precision of analysis. In particular embodiments of the invention, the level of 2-hydroxyglutarate and at least one second biomarker may be assayed to generate a hypoxic profile that can be compared to a reference or control profile, thereby diagnosing a subject as normoxic, chronically hypoxic, or acutely hypoxic.

Abstract: A Nutritional Supplement Composition promoting the increase, development, elevation and activation of the brain chemical “serotonin” in the “subjects” brain chemistry to improve mood, thought, emotions and, mental stability and functioning comprised of the constituents, Omega 3, Omega 6, Calcium Magnesium, and B-complex is described, as well as the method of administration, the usefulness of the present invention, and who would benefit from the administration of this present invention. This Nutritional Supplement composition may be used for all, in “age appropriate” dosages for different age “subjects”. This Nutritional Supplement Composition when administered daily will reduce and stabilize the “subjects” depression, anxiety, obsessive- compulsive behaviors stress related and other emotional and mental conditions. The above statement about the embodiment of the present invention will be further explained in more specific detail in the body of the description.

Abstract: A treatment is described for delivering oxygen to tissue, especially hypoxic tissue. A medium saturated with gas is delivered to the tissue. Dissolved gas is transferred from the medium to the tissue. Ultrasound is transmitted to the tissue to enhance the transfer of gas to the tissue.

Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Abstract: A process for preparing conventional water sources for providing “ideal state” cellular wellness benefits via topical hydration and natural transdermal, epithelial or epicellular absorption. The invention's process considers preconditioned water sources that have removed solids, dissolved solids, contaminants—both organic and inorganic and subsequently the method purifies the water respective of removing pathogens, and structures the water for cellular uptake in the form of vicinal grade water, with improved characteristics of ideal frequency, cluster size, pH, before safely introducing negative ORP (highly ionized state) to the water structure and organic nutrients or other supplemental pharmaceutical grade organic materials onto the skin or epithelial/epicellular environments surrounding tissue and cells.

Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.

Abstract: The subject of the present invention is a cosmetic composition of oil-in-water type comprising: (1) hydrophobic silica aerogel particles having a specific surface area per unit of mass (SM) ranging from 500 to 1500 m2/g and a size, expressed as volume-average diameter (D[0.5]), ranging from 1 to 1500 ?m ; (2) at least one gemini surfactant of formula in which R1 and R3 denote, independently of one another, an alkyl radical containing from 1 to 25 carbon atoms; R2 denotes a spacer consisting of a linear or branched alkylene chain containing from 1 to 12 carbon atoms; X and Y denote, independently of one another, a —(C2H4O)a—(C3H6O)bZ group; n ranges from 1 to 10 ; and (3) at least one fatty phase comprising at least one fatty substance chosen from solid fatty substances and pasty fatty substances.

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: A composition for use in the treatment of fistula, the composition comprising activated carbon.

Abstract: The invention relates to a method for the preparation of a silicic acid comprising extrudate, comprising the steps of: i) forming of stabilised silicic acid, by hydrolysing a silicon compound into orthosilicic acid and/or oligomers thereof in the presence of a stabilizing agent, which is a quaternary ammonium compound, or an amino-acid, or an amino acid source or combinations thereof; ii) mixing of the stabilised silicic acid with a carrier in an amount up to the loading capacity of the carrier for silicic acid; and iii) extruding the resulting mixture thereby forming the extrudate, to extrudates obtainable with the method, to an extrudate for use in the production of animal feed, feed supplement, human food and/or food supplement and of a pharmaceutical or cosmetic preparation, and for the treatment of infections, nails, hair, skin, teeth, collagen, connective tissue, bones, osteopenia, cell generation and degenerative (ageing) processes, and to a pharmaceutical composition comprising an extrudate.

Abstract: The present invention provides a non-irritating, sprayable wound dressing composition and a non-irritating, non-sprayable ointment for treating wounds in mammals such as horses or dogs. The composition of the present invention is made of an acceptable carrier and an active ingredient made of organic salts of naturally occurring cations having the capacity to facilitate healing of wounds.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: A method of enhancing health of a person includes administering stable water clusters to persons having an autoimmune disease, pain, a chronic disease, a mental disease, a genetic disease from malfunction of a normal DNA, being an athlete for improving his performance and alleviating soreness, suffering from overworking, stress and toxins etc., by drinking a solution containing stable water clusters, swallowing small objects which contain the stable water clusters, putting a topical cream which contains the stable water clusters on skin, breathing the stable water clusters through mouth, putting drops which contain the stable water clusters into eyes, ears or nose, cleaning colon with solution that contains the stable water clusters, eating food that contains the stable water clusters, injecting solution that contain the stable water clusters into blood vessel etc.

Abstract: A guided bone regeneration material is disclosed. The guided bone regeneration material includes biodegradable fibers produced by an electrospinning method. The biodegradable fibers produced by the method include a silicon-releasing calcium carbonate and a biodegradable polymer. The silicon-releasing calcium carbonate is a composite of siloxane and calcium carbonate of vaterite phase. The biodegradable fibers may be coated with apatite. When the guided bone regeneration material is immersed in a neutral aqueous solution, silicon species ions are eluted from the calcium carbonate. The guided bone regeneration material excels in bone reconstruction ability.

Abstract: An alternative method of delivery of homeopathic medicines by targeting delivery to the MALT's, especially of the intestinal tract and in high volumes.

Abstract: A tablet for use in a drip tray including an excipient selected so that the tablet will not fully dissolve in water at ambient temperature for a period of at least one month, more preferably up to 12 months, a biocide, at least one enzyme, preferably a proteolytic or hydrolase enzyme, and enzyme preserving means, such as a boron compound for maintaining enzyme activity in a moist environment. The excipient may be for example poly vinyl alcohols, high molecular weight polyethylene glycols, high molecular weight polypropylene glycols, esters or partial esters of polyethylene glycols or of polypropylene glycols, and high molecular weight thermoplastic surfactants. The invention also relates to methods for inhibiting the growth of biofilm in an drip tray or the like, including the step of adding to the tray a tablet according to the invention.

Abstract: The invention relates to compositions in a form of health drinks, capsules, tablets or powders. In particular the compositions improve individual's general health, maintain and improve regeneration of human connective tissue and simultaneously provide positive cosmetic effects for a better life and more happiness for all, male, female, young and old. The composition may include compounds such as silica compound, biotin, carnosine, hyaluronic acid, methylsulfonyl methane (MSM), dimethylethanolamine (DMEA) and omega-3-oil along with other components.

Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.

Abstract: The present invention relates to a method for manufacturing a brine with improved features for use in food as a condiment and for the preservation and treatment of fish and shellfish, improving the organoleptic and nutritional properties of the foods treated and/or cooked with it. The brine with improved features obtained according to the method of the present invention can furthermore be used as raw material for manufacturing intensely hydrating and mineralizing isotonic beverages for human consumption, as well as any food product requiring water in the manufacturing process, improving the nutritional properties thereof. It can also be used as raw material for manufacturing products with a high nutritional value in agriculture and stock raising, in the food industry, in other industries and in health treatments.

Abstract: An array of pharmaceutical formulations characterized by the presence of molecular oxygen comprising four elements which, in combination, furnish benefits for the health of patients with HIV AIDS: (i) weight increase of the patient; (ii) increase of appetite; (iii) reduction of diarrhea; (iv) reduction of the wasting syndrome; (v) increase of stability of mood; (vi) increase of muscular mass. (vii) decrease of opportunistic diseases, in particular infections caused by Candida, herpes virus, cytomegalovirus, Kaposi's sarcoma; (viii) prolongation of the period wherein the patient does not require to take antiretrovirals; (ix) increase of acceptance of pharmacological treatment; x. reduction of gastritis, nausea or vomiting, headache; (xi) reduction of cases with anemia or thrombocytopenia; and (xii) a change in the phase of the disease in the patient.

Abstract: The present invention generally relates to bioactive antibacterial materials and composites that enhance bone growth while preventing surgical site infection. The present invention also relates to bioactive antibacterial materials and composites that include a bimodal bioactive glass particle size distribution. The bioactive antibacterial composite finds utility in a variety of clinical applications including spine and orthopaedic procedures.

Abstract: A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level.

Abstract: The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer.

Abstract: Methods are provided for selecting a new therapeutic indication for at least one first pharmaceutical comprising the steps of: generating a drug-side effect (SE) association for said at least one first pharmaceutical; generating a disease-side effect (SE) association for at least one disease or disorder and at least one second pharmaceutical intended for treatment of said at least one disease or disorder; determining an association strength between the drug-side effect (SE) association and the disease-side effect (SE) association; selecting said at least one disease or disorder as a new therapeutic indication for said at least one first pharmaceutical if said at least one first pharmaceutical induces at least one side effect which is the same as at least one side effect induced by at least one second pharmaceutical intended for treatment of said at least one disease or disorder.

Abstract: Disclosed is a multiple separation filter including a microfiltration membrane, an active carbon-based filter and a ceramic filter stacked in order, wherein the active carbon-based filter is obtained by mixing active carbon with at least one selected from zeolite, gold, silver and a mixture thereof, treating the mixture with plasma gas of 60,000° C. to 70,000° C., and then quenching the mixture to ?200° C. to ?273° C. under vacuum, and the ceramic filter is obtained by quenching plasma gas generated by heating magnesium at 60,000° C. to 70,000° C. to ?200° C. to ?273° C. under vacuum. Disclosed also is antioxidant water obtained by using the multiple separation filter. The antioxidant water has a negative oxidation reduction potential.

Abstract: A cosmetic composition comprising at least one compound selected from bioactive/biocompatible microparticulates such as bioactive glass or bioactive ceramics, and an intradermal delivery vehicle selected from the group consisting of hyaluronans, hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid in an amount sufficient to facilitate deposition and penetration of said bioactive microparticulates through tissue at a site to be treated.

Abstract: A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue. This method comprises the administration of a combination composition comprising (a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphate derivative thereof.

Abstract: The invention encompasses antidotal food products containing activated charcoal for ingestion into the gastrointestinal tract of a user for treating various gastrointestinal disorders. The antidotal food product is orally administered having the visual appearance and physical properties which enables the desire on the part of young children to chew and ingest the food product.

Abstract: The invention relates deuterium depleted water containing 0.01 to 135 ppm deuterium, preferably 105 to 125 ppm deuterium, for use in the treatment of insulin resistance. Further object of the invention is deuterium depleted food product containing 0.01 to 135 ppm deuterium, preferably 105 to 125 ppm deuterium, for use in the treatment of insulin resistance.

Abstract: In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 500 mg of vitamin C; about 400 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folic acid; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 75 mcg of biotin; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 10 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 400 mcg of lutein; about 125 mcg of lycopene; and at least one or more excipients.

Abstract: Disclosed are formulations for enhancing the in vivo colonization of probiotic microorganisms that include digestive enzymes and probiotic microorganisms, and polysorbate surfactants. The enzymes include lactogenic enzyme formulations that promote growth of Lactobacillus probiotics, bifidogenic enzyme formulations that promote growth of Bifidobacterium probiotics and combination formulations that benefit both types of probiotics. It has been discovered that certain polysorbate surfactants, including polysorbate-60 and polysorbate-80, further promote probiotic microorganism growth, when used with the enzyme formulations. The formulations are preferably compounded as dry powders, to avoid water reaction with the enzymes in blended formulations. Such formulations can be contained in capsules, tablets, packets or bottles and administered orally, either sequentially or in one combined formulation.

Abstract: The invention relates to the use deuterium depleted water (DDW) for the preparation of combined pharmaceutical compositions for the prevention or treatment of tumorous diseases, where the composition comprises DDW with deuterium content of 0.01 to 135 ppm and one or more antineoplastic agent(s), optionally together with one or more usual pharmaceutical auxiliary material(s). Further, the invention relates to pharmaceutical compositions for adjuvant treatment of tumorous diseases, where the composition comprises DDW with deuterium content of 0.01 to 135 ppm and one or more antineoplastic agent(s), optionally together with one or more usual pharmaceutical auxiliary material(s). The invention also relates to aqueous pharmaceutical compositions usually applied in curing where the aqueous component is DDW with deuterium content of 0.01 to 135 ppm.

Abstract: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.

Abstract: The invention relates to solutions carrying high levels of oxygen, e.g. to aqueous solutions having an oxygen concentration of at least 30 mg/L, especially at least 70 mg/L, and to uses thereof. The aqueous solutions contain colloidal minerals which help stabilise the high oxygen levels. The super-oxygenated fluids may be used to affect the viability, growth and maintenance of cells, tissues and organs.

Abstract: The present invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of virus-based diseases of the respiratory tract.

Abstract: Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from ?1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Abstract: Dissolved oxygen may be generated by adding a peroxide to a fluid stream and then catalytically decomposing the peroxide to generate oxygen. As the peroxide is catalytically decomposed, the oxygen may solubilize in a surrounding fluid so as to provide dissolved oxygen. In some examples, the amount of peroxide added to the fluid stream is controlled such that substantially all of the hydrogen peroxide added to the fluid stream catalytically decomposes and yet the dissolved oxygen concentration of the fluid stream does not exceed a dissolved oxygen saturation limit for the fluid stream.

Abstract: The invention disclosed a novel mesoporous silica-based xerogel and its use in hemorrhage control. The mesoporous silica-based xerogel material has tunable mesopores (1-50 nm), high specific surface area (100-1400 m2/g), macroscopical morphology (powder, film, disc, column, etc.) and adjustable compositions (SiO2, CaO and P2O5, etc.) as well as good biodegradation. The mesoporous silica-based xerogels herein effectively promote the blood clotting under various conditions including slow and severe hemorrhage, even at the blood oozing site of bone defect. Meanwhile, the networks of silica-based xerogel with good elastic and mechanic properties, formed by adsorbing a large amount of water, can modulate the cell behavior and tissue growth, and thus promote the wound healing. Additionally, due to the mesoporous structure, the materials have the potential to load drug, thrombin and bioactive factors, which is favorable for the therapeutical efficacy.

Abstract: A method and composition for preventing and treating all forms of osteonecrosis of the jaw are disclosed. The composition is comprised of 0.005%-2.0% weight/volume (w/v) chlorine dioxide source, such as sodium chlorite, chlorite ion, stabilized chlorine dioxide or similar and may take the form of a paste, gel, rinse, spray, powder, varnish or similar. The method for treatment and prevention includes the application of the composition in the oral cavity and other body areas affected by osteonecrosis of the jaw.

Abstract: The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of Clostridia sp.

Abstract: A block co-polymer includes a water soluble carrier block; an amino acid-based or acrylic acid-based block; and the amino acid-based or acrylic acid-based block includes a fluorinated alkyl group or a fluorinated alkylene glycol group.